Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Assets (2016 - 2025)

Celldex Therapeutics (CLDX) has 15 years of Return on Assets data on record, last reported at 0.42% in Q4 2025.

  • For Q4 2025, Return on Assets fell 22.0% year-over-year to 0.42%; the TTM value through Dec 2025 reached 0.42%, down 22.0%, while the annual FY2025 figure was 0.38%, 13.0% down from the prior year.
  • Return on Assets reached 0.42% in Q4 2025 per CLDX's latest filing, down from 0.33% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.16% in Q4 2021 and bottomed at 0.43% in Q3 2023.
  • Average Return on Assets over 5 years is 0.28%, with a median of 0.28% recorded in 2022.
  • Peak YoY movement for Return on Assets: rose 25bps in 2024, then fell -22bps in 2025.
  • A 5-year view of Return on Assets shows it stood at 0.16% in 2021, then crashed by -99bps to 0.31% in 2022, then fell by -22bps to 0.38% in 2023, then skyrocketed by 48bps to 0.2% in 2024, then crashed by -115bps to 0.42% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Assets were 0.42% in Q4 2025, 0.33% in Q3 2025, and 0.28% in Q2 2025.